Shots:

• The P-III APSEN study involve assessing of Brukinsa (zanubrutinib) vs AbbVie's Imbruvica (ibrutinib) in 229 patients with r/r or TN WM across 61 centers in the US- EU and Australia
• The P-III APSEN study resulted in not meeting its 1EPs- i.e- superiority in CR & VGPR rate in up to 3yrs.; in r/r patients & overall patient population: VGPR rate (28.9% & 28.4% vs 19.8% & 19.2%); MRR (78.3% & 77.5% vs 80.2% & 77.8%); PFS @12mos. (92.4% & 85.9% vs 89.7% & 87.2%); OS @12mos. (98.8% & 92.5% vs 97.0% & 93.9%); safety profile were similar; respectively
• Brukinsa (BGB-3111) is a BTK inhibitor- currently being evaluated in multiple clinical studies globally including China as a potential monothx. or in combination with other therapies targeting B cell malignancies

Click here ­to­ read full press release/ article | Ref: BeiGene | Image: USCA